iBio, Inc.

NASDAQ:IBIO

Biotechnology

Healthcare
$0.85 +0.00%

+$0.00 today

Market cap
$59.75M
Beta
1.29
P/E (TTM)
-3.6
EPS (TTM)
-$0.32
52W Low $0.78High $3.82

Volume 0.84M

Average 0.81M

IBIO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

iBio, Inc.NASDAQ: IBIO

Research & Development · Q4 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q4 FY2026 research & development of $8.56M rose 165.5% year over year, ahead of the +136.3% change in trailing-twelve-month research & development. Sequentially, it rose 163.0% from the prior quarter. Over 3 fiscal years it compounded at +23.9% a year.

Context

  • Research & development amounted to 19643.0% of revenue in FY2026, up 17565.0 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +165.5% holds above the trailing-twelve-month pace of +136.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$8.56M+163.0% QoQ
Last fiscal yearJun 2026
$19.64M+136.3% YoY
LTMJun 2026
$19.64M+136.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+165.5%——
1 year+136.3%——
3-year CAGR+23.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2026
19.64M USD
Year-over-year change
+136.3%
4-year CAGR
+18.9%

Research & Development vs competitors

How IBIO compares with its peers on the latest reported figures

  • IBIO's LTM Jun 2026 research & development of $19.64M is the 3rd highest of the 4 companies compared; the peer median is $23.82M.
  • Its year-over-year change of +136.3% is the highest of 4, against a peer median of -28.9%.
  • Research & development amounts to 19643.0% of revenue for IBIO, versus a peer median of 1624.7%.
IBIO Competitors Peer median
Research & Development for IBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BOLDBoundless Bio, Inc.LTM Mar 2026$42.44M -21.4%+6.5%—
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$23.82M -28.9%-5.7%—
IBIOiBio, Inc.LTM Jun 2026$19.64M +136.3%+23.9%19643.0%
RLYBRallybio CorporationLTM Mar 2026$13.94M -59.3%-21.6%1624.7%
Peer median (excluding IBIO) $23.82M-28.9%-5.7%1624.7%

Competitors are the stored peer set for IBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Revenue1.88M0225K400K100K
Cost of Revenue3.79M0000
Gross Profit(1.91M)0225K400K100K
Gross Margin-101.2%—100.0%100.0%100.0%
Research & Development9.83M10.33M5.19M8.31M19.64M
Selling, General & Admin17.96M18.45M11.67M10.69M10.6M
Operating Expenses27.79M29.34M16.86M19M35.24M
Depreciation & Amortization3.79M1.38M1.25M1.13M646K
EBITDA(25.72M)(27.85M)(14.02M)(17.04M)(32.35M)
EBITDA Margin-1365.3%—-6231.6%-4259.8%-32345.0%
Operating Income(29.7M)(29.34M)(16.63M)(18.6M)(35.14M)
Operating Margin-1576.3%—-7392.9%-4650.5%-35141.0%
Interest Income177K213K363K437K2.15M
Interest Expense1.41M83K172K212K53K
Other Income / Expenses184K32K1.19M225K2.1M
Income Before Tax(29.51M)(29.31M)(15.44M)(18.38M)(33.04M)
Pre-Tax Margin-1566.5%—-6863.6%-4594.3%-33044.0%
Income Tax Expense00000
Net Income(50.39M)(65.01M)(24.91M)(18.38M)(33.04M)
Net Margin-2674.7%—-11069.8%-4594.3%-33044.0%
EPS (Basic)(2,889.06)(106.18)(6.50)(1.75)(0.32)
EPS (Diluted)(2,889.06)(106.18)(6.50)(1.75)(0.32)
Weighted Avg Shares17.44K612.25K3.83M10.5M104.06M
Weighted Avg Shares (Diluted)17.44K612.25K3.83M10.5M104.06M

iBio, Inc.

NASDAQ:IBIO

Intrinsic Alpha fair value

Locked

Current Price

$0.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.